SEROBA/KURMA-PARTNERS
Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/
Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available.
Seroba joined the consortium of investors leading the planned second closing of the Series B financing round of an additional €11.5 million ($12.4 million) with participation from Kurma Growth Opportunities Fund supporting Vico to continue to advance their lead clinical program and further develop a portfolio of novel antisense oligonucleotides. Existing investors include Ackermans & van Haaren (AvH), Droia Ventures, EQT Life Sciences, Eurazeo, Kurma Biofund, Polaris Partners and Pureos Bioventures, for a total Series B financing round of €65.8 million ($70.7 million).
Catello Somma, Partner at Seroba, commented:
“We are extremely proud to support Vico in this financing round and join the existing investors. The growth capital will help the Company to bolster its clinical programs to deliver life-changing outcomes for patients with polyQ diseases, such as SCA and Huntington's. We are excited to partner with Vico and its remarkable team as the Company advances its programs.”
Daniel Parera and Jean-Francois Rivassou, Partners at Kurma, commented:
“Vico is another very nice example of a company where Kurma Partners acted as a co-founding investor (Rémi Droller on behalf of Kurma Biofund III alongside with EQT Life Sciences) that has progressed into clinical development, where Kurma Growth Opportunities Fund is able to add further support to the Company and its experienced management team in the continuation of Vico’s path together with existing investors.”
About Seroba.
Seroba is a European life sciences venture capital firm based in Dublin, Paris and Milan, investing from its fourth Fund. Seroba focuses on value creation through backing cutting-edge biotech and medtech innovation that will transform the treatment of patients, addressing unmet medical needs. The Seroba team has deep industry, operational and investing experience and an extensive global network. Seroba likes to work with entrepreneurs who share its passion for success and with investors who share the same goal of improving human health while driving financial returns.
Follow Seroba’s story at https://serobavc.com/
About Kurma Partners
Founded in July 2009 and based in Paris and Munich, Kurma Partners is a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital. Kurma invests through its funds Kurma Biofund I, II and III, Kurma Diagnostics and Kurma Diagnostics 2, and the most recent Kurma Growth Opportunities Fund, for which this is the eighth investment. Kurma collaborates through extensive networks of prestigious research and academic institutes, premier cluster organizations and hospitals connecting with established industry players. Kurma Partners is part of the Eurazeo Group.
www.kurmapartners.com (www.eurazeo.com/en)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240623484065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 07:00:00 CEST | Press release
Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively imp
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 202522.5.2025 23:43:00 CEST | Press release
Data from Phase 3 MANEUVER study demonstrating significant improvements in physical function and symptoms in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, to be featured in oral presentationLatest results for potential first-in-class anti-CEACAM5 ADC precemtabart tocentecan (M9140) highlight strong rationale for further development in colorectal cancer (CRC)Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers.
Cooperation between Topcon Positioning Systems and Amberg Technologies Ltd.22.5.2025 22:17:00 CEST | Press release
Topcon Positioning Systems and Amberg Technologies Ltd. have initiated a close collaboration to enable interoperability between Topcon’s sensor solutions and Amberg Technologies’ software and hardware platforms for rail and tunnel applications. This marks the first step towards offering fully integrated solutions to our shared customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522363239/en/ Luc Le Maire, Senior Vice President, Topcon (left) and Johannes Mueller, CEO, Amberg Technologies. About Topcon Positioning Systems Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, X, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Cor
LBT Holdings Ltd. Acquires Gonet Bank & Trust Limited, Introducing Bank of Nassau to Uphold the Finest Traditions of Private Banking22.5.2025 18:29:00 CEST | Press release
LBT Holdings Ltd., in partnership with Gonet SA, is pleased to announce the successful acquisition of Gonet Bank & Trust Limited, a distinguished Bahamas-based private bank formerly owned by Gonet SA. The transaction, which has received full regulatory approval from the Swiss Financial Market Supervisory Authority (FINMA), the Central Bank of The Bahamas (CBOB), and The Securities Commission of The Bahamas (SCB), marks a significant milestone for both organizations. Effective immediately, LBT Holdings Ltd. assumes 100% ownership of Gonet Bank & Trust Limited. As part of this strategic transition, Gonet Bank & Trust Limited will be rebranded as Bank of Nassau 1982 Limited, reflecting its renewed vision and commitment to excellence in private banking and wealth management. This acquisition strengthens the position of all parties in the global financial services sector, enabling expanded service offerings while upholding the highest standards of client-centric banking. Bank of Nassau 1982
Andersen Global indvier medlemsfirmaer i Usbekistan og styrker sin tilstedeværelse i Centralasien22.5.2025 16:34:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Centralasien med tilføjelsen af Andersen i Usbekistan, hvilket er en del af den fortsatte udvidelse af organisationens kapaciteter i regionen. Firmaet blev grundlagt i 2009 under navnet Virtus Leo og ledes af den administrerende partner Alisher Zaynutdinov. Siden 2021 har det været samarbejdspartner med Andersen Global. Teamet tilbyder tjenester inden for skatte- og juraforhold inden for en bred vifte af sektorer, herunder overholdelse af skattelovgivningen for selskabser og enkeltpersoner, rådgivning om direkte og indirekte skat, transferpriser, ledelsesrapportering og -analyse, selskabsledelse, konkurrenceret og antitrust, selskabs- og bankret, arbejds- og ansættelsesret, retssager og undersøgelser, fusioner og opkøb, fast ejendom, energi, immaterialret samt familieret. "I kraft af vores professionalisme, gennemsigtighed og evne til at se løsninger samt analytiske tilgang til alle opgaver er vi godt positioneret til at rådgive vores klien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom